Scientists engineer ready-to-use cancer-fighting T cells for solid tumors

Good news! Cancer is history (soon)!

"Key takeaways

• ... researchers have developed a way to mass-produce cancer-fighting T cells from blood stem cells found in cord blood, engineered to target a protein found in many solid tumors — creating uniform batches instead of custom treatments for each patient.
• This way, scientists ensure that all the T cells they produce carry the same single tumor-targeting receptor, avoiding the random receptors that can attack healthy tissue and cause a dangerous condition called graft-versus-host disease.
• In mouse models of ovarian cancer and melanoma, a single dose kept tumors in check and extended survival, outperforming conventional donor T cells, which caused toxic side effects in the same tests.

...

Rather than starting with mature, donor-derived T cells, the researchers began a step earlier — with blood stem cells found in cord blood, which naturally give rise to every type of blood and immune cell. They then added a gene for a receptor that targets NY-ESO-1, a protein found in many solid tumors. Fragments of NY-ESO-1 get pushed to the outer surface and displayed there, name-tag style. The researchers then grew these engineered stem cells into T cells in the lab. ...

“From a small number of cord blood stem cells, we can generate trillions of therapeutic cells — enough for thousands of doses — within about six weeks,” ...  “At an estimated $5,000 per dose, this approach would be far more accessible than today’s therapies.” ..."

From the highlights and abstract:

"Highlights

• HSPC-derived AlloESO-T cells enable scalable, feeder-free T cell manufacturing

• AlloESO-T cells overcome autologous complexity, HLA restriction, and donor variability

• AlloESO-T cells display tumor homing, durable persistence, and TCR/NKR dual targeting

• AlloESO-T cells show minimal GvHD/CRS risk and stable hypoimmunogenicity

Summary

Adoptive T cell therapy for solid tumors is limited by autologous manufacturing complexity and, in allogeneic settings, risks including graft-versus-host disease (GvHD), HLA restriction, and donor variability.

We develop a scalable, feeder-free platform to differentiate gene-engineered hematopoietic stem and progenitor cells (HSPCs) into allogeneic, NY-ESO-1-specific cytotoxic T (AlloESO-T) cells.

Product phenotype, function, tumor homing, and safety are assessed against solid tumor models and benchmarked to peripheral blood mononuclear cell (PBMC)-derived TCR-engineered T cells. AlloESO-T cells display a uniform cytotoxic phenotype, with dual tumor targeting through a transgenic TCR and natural killer receptors.

Relative to PBMC-derived counterparts, AlloESO-T cells show superior cytotoxicity, selective solid-tumor homing, durable killing persistence, and resilience to immune evasion.

They also maintain low GvHD and cytokine release syndrome risk, while retaining stable hypoimmunogenic features. These findings establish HSPC-derived AlloESO-T cells as an off-the-shelf, mono-specific cytotoxic T cell therapy with scalable manufacturing, enhanced efficacy, and improved safety, which support broad applicability of AlloESO-T cells across solid tumors."

UCLA scientists engineer ready-to-use cancer-fighting T cells for solid tumors | UCLA "A new stem cell-based platform produces uniform T cells that attack solid tumors two ways while avoiding a dangerous side effect"

Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors (open access)

Graphical abstract

Figure 1 Generation and characterization of Allo/15ESO-T cells